Dolutegravir

1. Dolutegravir (GSK1349572) - CAS 1051375-16- 6 Catalog number: B0084-438457 Dolutegravir is a two-metal-binding HIV-1 integrase inhibitor with IC50 of 2.7 nM, with modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. It blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Inhibitor Targets HIV Integrase SARS-CoV-2 Molecular Formula C20H19F2N3O5 Molecular Weight 419.38 Ordering Information Catalo Catalo g g Number Number Siz Siz e e Pric Pric e e Stoc Stoc k k Quantity Quantity In stoc k B0084- 438457 25 mg $298 0 Order Now Bulk Inquiry Chemical Information Category

2. Inhibitor Molecular Formula C20H19F2N3O5 Molecular Weight 419.38 Specification Properties QC Data Reference Reading Purity Purity ≥98% Related CAS Related CAS 1051375-19-9 (sodium) 1051375-16-6 (free) Synonyms Synonyms GSK-1349572; GSK 1349572; GSK1349572; Tivicay Clinical Trial Information NCT Number NCT Number Title Title Condition Or Condition Or Disease Disease Phase Phase Start Start Date Date Sponsor Sponsor Status Status NCT00042289 Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy HIV Infections Phase 4 March 2003 National Institute of Allergy and Infectious Diseases (NIAID) Recruiting NCT00537966 Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study HIV Infections January 2002 University of Zurich Recruiting NCT00555035 GSK1349572 First Time in Human Study Healthy Subjects Phase November 2007 GlaxoSmithKline Completed 1

3. NCT00631592 GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study Healthy Subjects Phase February 2008 ViiV Healthcare Completed 1 NCT00708110 Phase IIa Dose- ranging Study of GSK1349572 in HIV-1 Infected Adults Infection, Human Immunodeficiency Virus Phase 2 June 2008 ViiV Healthcare Completed Preparing Stock Solutions 1 mg 1 mg 5 mg 5 mg 10 mg 10 mg ConcentrationVolumeMass ConcentrationVolumeMass 1 mM 2.3845 mL 11.9224 mL 23.8447 mL 5 mM 0.4769 mL 2.3845 mL 4.7689 mL 10 mM 0.2384 mL 1.1922 mL 2.3845 mL 50 mM 0.0477 mL 0.2384 mL 0.4769 mL https://www.bocsci.com/dolutegravir-gsk1349572-cas-1051375-16-6-item- 438457.html